Munich – vasopharm GmbH today announced the successful completion of a Series F financing round totalling EUR 5 million. The biopharmaceutical company focuses on novel therapeutics for the treatment of cerebro- and cardiovascular diseases. The round was led by existing investors HeidelbergCapital Private Equity and Entrepreneurs Fund (EF Investments S.à.r.l.). Bayern Kapital, another existing investor, also participated in the Series F round. The consortium was joined by new investors Hanseatic Asset Management LBG and Dr Andrew Clark, Chairman of the Board of vasopharm. The new consortium also acquired the shares of one of the founding investors.
A team led by lead partner and venture capital expert Stefan-Ulrich Müller advised vasopharm on all aspects of the transaction. CMS Hasche Sigle has been advising the company for many years.
CMS Hasche Sigle
Stefan-Ulrich Müller, Venture Capital, Lead Partner
Alexander Frauer, Venture Capital
Katrin Bauer, Venture Capital
Stefan Lehr, Competition